Developing better treatments for patients in need

At TNF Pharmaceuticals^®, we’re partnering with internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that treat the causes of disease and decline rather than simply focusing on the symptoms. We are working to rapidly advance MYMD-1® and Supera-CBD in clinical trials while identifying and validating additional novel targets.

We recently partnered with The Bascom Palmer Eye Institute, the number one eye hospital in the US, to preclinically evaluate MYMD-1® as a potentially safe, effective, and easily administrable treatment for traumatic optic neuropathy (TON). In addition, we have had collaborations with highly regarded institutions including the Johns Hopkins University School of Medicine which recently resulted in publication of a preclinical study in Journal of Gerontology: Biological Sciences.

Key findings on MYMD-1® 

MYMD-1® regulates TNF-alpha, an essential first line responder to acute infection  

Our research shows that, at only about 146 Daltons, MYMD-1® is the first oral TNF-alpha regulator capable of crossing the blood-brain barrier, which could enable it to address brain-related diseases. 

Unlike other therapies, MYMD-1® selectively blocks TNF-alpha when it becomes overactivated in autoimmune diseases and cytokine storms, mitigating the risk of life-threatening infections. Additionally, MYMD-1® selectively inhibits TNF-alpha production in lymphocytes but not in macrophages and as a result does not block the ability of the immune system to fight bacterial and viral infections.